Design, Virtual Screening, and Synthesis of Antagonists of αiIbβ3 as Antiplatelet Agents

Journal of Medicinal Chemistry

Volumn 58, Issue 19, 2015, Pages 7681-7694

  Polishchuk, Pavel G ^a   Samoylenko, Georgiy V ^a   Khristova, Tetiana M ^a,b   Krysko, Olga L ^a   Kabanova, Tatyana A ^a   Kabanov, Vladimir M ^a   Kornylov, Alexander Yu ^a   Klimchuk, Olga ^b   Langer, Thierry ^c   Andronati, Sergei A ^a   Kuzmin, Victor E ^a   Krysko, Andrei A ^a   Varnek, Alexandre ^b  

^a A V BOGATSKY PHYSICO CHEMICAL INSTITUTE   (Ukraine)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 BOC PIPERAZIN 1 YL) 6 AMINO 3H QUINAZOLIN 4 ONE; 2 (4 BOC PIPERAZIN 1 YL) 6 NITRO 3H QUINAZOLIN 4 ONE; 2 (N BUTYLSULFONYL) 3 [3 [(2 BOC 1,2,3,4 TETRAHYDROISOQUINOLINE 7 CARBONYL)AMINO]PROPIONYL]AMINOPROPIONIC ACID; 2 (PHENYLSULFONYL) 3 [3 [(2 BOC 1,2,3,4 TETRAHYDROISOQUINOLINE 7 CARBONYL)AMINO]PROPIONYL]AMINOPROPIONIC ACID; 2 CHLORO 6 NITRO 3H QUINAZOLIN 4 ONE; 3 N BOC AMINO N [2 (4 BOC PIPERAZIN 1 YL) 4 OXO 3H QUINAZOLIN 6 YL]PROPIONAMIDE; 4 N BOC AMINO N [2 (4 BOC PIPERAZIN 1 YL) 4 OXO 3H QUINAZOLIN 6 YL]PROPIONAMIDE; 6 NITROQUINAZOLIN 2,4 DIONE; ADENOSINE DIPHOSPHATE; ALPHA2B BETA3 ANTAGONIST; ANTITHROMBOCYTIC AGENT; CHLORIDE 2 (N BUTYLSULFONYL) 3 [3 [(2 BOC 1,2,3,4 TETRAHYDROISOQUINOLINE 7 CARBONYL)AMINO]PROPIONYL]AMINOPROPIONIC ACID; CHLORIDE 2 (PHENYLSULFONYL) 3 [3 [(2 BOC 1,2,3,4 TETRAHYDROISOQUINOLINE 7 CARBONYL)AMINO]PROPIONYL]AMINOPROPIONIC ACID; DICHLORIDE 3 AMMONIUM N [2 (4 PIPERAZINIUM 1 YL) 4 OXO 3H QUINAZOLIN 6 YL]PROPIONAMIDE; DICHLORIDE 4 AMMONIUM N [2 (4 PIPERAZINIUM 1 YL) 4 OXO 3H QUINAZOLIN 6 YL]PROPIONAMIDE; DICHLORIDE N [2 (4 PIPERAZINIUM 1 YL) 4 OXO 3H QUINAZOLIN 6 YL]PIPERIDINIUM 4 CARBOXAMIDE; N [2 (4 BOC PIPERAZIN 1 YL) 4 OXO 3H QUINAZOLIN 6 YL] 1 BOC PIPERIDINE 4 CARBOXAMIDE; TIROFIBAN; UNCLASSIFIED DRUG; ARGINYL-GLYCYL-ASPARTYL-PHENYLALANINE; FIBRINOGEN RECEPTOR; MOLECULAR LIBRARY; OLIGOPEPTIDE; PEPTIDOMIMETIC AGENT;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; IC50; IN VITRO STUDY; MOLECULAR DOCKING; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PRECLINICAL STUDY; PROCEDURES; SYNTHESIS;

CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; OLIGOPEPTIDES; PEPTIDOMIMETICS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SMALL MOLECULE LIBRARIES;

EID: 84943736669     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00865     Document Type: Article

References (85)

1. Libby, P.; Theroux, P. Pathophysiology of Coronary Artery Disease Circulation 2005, 111, 3481-3488 10.1161/CIRCULATIONAHA.105.537878
2. Davì, G.; Patrono, C. Platelet Activation and Atherothrombosis N. Engl. J. Med. 2007, 357, 2482-2494 10.1056/NEJMra071014
3. Ruf, A.; Patscheke, H. Flow Cytometric Detection of Activated Platelets: Comparison of Determining Shape Change, Fibrinogen Binding, and P-Selectin Expression Semin. Thromb. Hemostasis 1995, 21, 146-151 10.1055/s-2007-1000389
4. Massberg, S.; Brand, K.; Grüner, S.; Page, S.; Müller, E.; Müller, I.; Bergmeier, W.; Richter, T.; Lorenz, M.; Konrad, I.; Nieswandt, B.; Gawaz, M. A Critical Role of Platelet Adhesion in the Initiation of Atherosclerotic Lesion Formation J. Exp. Med. 2002, 196, 887-896 10.1084/jem.20012044
5. Furie, B.; Furie, B. C. Mechanisms of Thrombus Formation N. Engl. J. Med. 2008, 359, 938-949 10.1056/NEJMra0801082
6. Offermanns, S. Activation of Platelet Function Through G Protein-Coupled Receptors Circ. Res. 2006, 99, 1293-1304 10.1161/01.RES.0000251742.71301.16
7. Wang, X.; Dorsam, R. T.; Lauver, A.; Wang, H.; Barbera, F. A.; Gibbs, S.; Varon, D.; Savion, N.; Friedman, S. M.; Feuerstein, G. Z. Comparative Analysis of Various Platelet Glycoprotein IIb/IIIa Antagonists on Shear-Induced Platelet Activation and Adhesion J. Pharmacol. Exp. Ther. 2002, 303, 1114-1120 10.1124/jpet.102.038513
8. Clappers, N.; Brouwer, M. A.; Verheugt, F. W. A. Antiplatelet treatment for coronary heart disease Heart 2007, 93, 258-265 10.1136/hrt.2005.071209
9. Freson, K.; Thys, C.; Wittevrongel, C.; Geet, C. V. Mechanisms of Action and Targets for Actual and Future Antiplatelet Drugs Mini-Rev. Med. Chem. 2006, 6, 719-726 10.2174/138955706777435661
10. Andronati, S. A.; Karaseva, T. L.; Krysko, A. A. Peptidomimetics-Antagonists of the Fibrinogen Receptors: Molecular Design, Structures, Properties and Therapeutic Applications Curr. Med. Chem. 2004, 11, 1183-1211 10.2174/0929867043365314
11. Hartman, G. D.; Egbertson, M. S.; Halczenko, W.; Laswell, W. L.; Duggan, M. E.; Smith, R. L.; Naylor, A. M.; Manno, P. D.; Lynch, R. J. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors J. Med. Chem. 1992, 35, 4640-4642 10.1021/jm00102a020
12. Scarborough, R. M.; Naughton, M. A.; Teng, W.; Rose, J. W.; Phillips, D. R.; Nannizzi, L.; Arfsten, A.; Campbell, A. M.; Charo, I. F. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa J. Biol. Chem. 1993, 268, 1066-1073
13. Coller, B. S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex J. Clin. Invest. 1985, 76, 101-108 10.1172/JCI111931
14. Antoniucci, D. Differences among GP IIb/IIIa inhibitors: different clinical benefits in non-ST-segment elevation acute coronary syndrome percutaneous coronary intervention patients Eur. Heart J. Suppl. 2007, 9, A32-A36 10.1093/eurheartj/sul069
15. Berkowitz, S. D.; Sane, D. C.; Sigmon, K. N.; Shavender, J. H.; Harrington, R. A.; Tcheng, J. E.; Topol, E. J.; Califf, R. M. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization J. Am. Coll. Cardiol. 1998, 32, 311-319 10.1016/S0735-1097(98)00252-6
16. McClure, M. W.; Berkowitz, S. D.; Sparapani, R.; Tuttle, R.; Kleiman, N. S.; Berdan, L. G.; Lincoff, A. M.; Deckers, J.; Diaz, R.; Karsch, K. R.; Gretler, D.; Kitt, M.; Simoons, M.; Topol, E. J.; Califf, R. M.; Harrington, R. A. Clinical Significance of Thrombocytopenia During a Non-ST-Elevation Acute Coronary Syndrome: The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience Circulation 1999, 99, 2892-2900 10.1161/01.CIR.99.22.2892
17. Bougie, D. W.; Wilker, P. R.; Wuitschick, E. D.; Curtis, B. R.; Malik, M.; Levine, S.; Lind, R. N.; Pereira, J.; Aster, R. H. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa Blood 2002, 100, 2071-2076
18. Bougie, D. W.; Rasmussen, M.; Zhu, J.; Aster, R. H. Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin Blood 2012, 119, 6317-6325 10.1182/blood-2012-01-406322
19. Blue, R.; Murcia, M.; Karan, C.; Jiroušková, M.; Coller, B. S. Application of high-throughput screening to identify a novel αIIb-specific small- molecule inhibitor of αIIbβ3-mediated platelet interaction with fibrinogen Blood 2008, 111, 1248-1256 10.1182/blood-2007-08-105544
20. Zhu, J.; Zhu, J.; Negri, A.; Provasi, D.; Filizola, M.; Coller, B. S.; Springer, T. A. Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening Blood 2010, 116, 5050-5059 10.1182/blood-2010-04-281154
21. Zhu, J.; Choi, W.-S.; McCoy, J. G.; Negri, A.; Zhu, J.; Naini, S.; Li, J.; Shen, M.; Huang, W.; Bougie, D.; Rasmussen, M.; Aster, R.; Thomas, C. J.; Filizola, M.; Springer, T. A.; Coller, B. S. Structure-Guided Design of a High-Affinity Platelet Integrin αIIbβ3 Receptor Antagonist That Disrupts Mg2+ Binding to the MIDAS Sci. Transl. Med. 2012, 4, 125ra32-125ra32 10.1126/scitranslmed.3003576
22. Jiang, J.-k.; McCoy, J. G.; Shen, M.; LeClair, C. A.; Huang, W.; Negri, A.; Li, J.; Blue, R.; Harrington, A. W.; Naini, S.; David Iii, G.; Choi, W.-S.; Volpi, E.; Fernandez, J.; Babayeva, M.; Nedelman, M. A.; Filizola, M.; Coller, B. S.; Thomas, C. J. A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor Bioorg. Med. Chem. Lett. 2014, 24, 1148-1153 10.1016/j.bmcl.2013.12.122
23. Gaulton, A.; Bellis, L. J.; Bento, A. P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J. P. ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 2012, 40, D1100-D1107 10.1093/nar/gkr777
24. Krysko, A. A.; Chugunov, B. M.; Malovichko, O. L.; Andronati, S. A.; Kabanova, T. A.; Karaseva, T. L.; Kiriyak, A. V. Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid Bioorg. Med. Chem. Lett. 2004, 14, 5533-5535 10.1016/j.bmcl.2004.09.002
25. Andronati, S. A.; Krysko, A. A.; Chugunov, B. M.; Kabanova, T. A.; Artemenko, A. G. 4-(Isoindolin-5-yl)amino-4-oxobutyryl-β-alkoxyphenyl-β-alanines, new RGDF mimetics. Synthesis, affinity to fibrinogen receptors, antiaggregatory properties, and their correlation with the hydrophobicity Russ. J. Org. Chem. 2006, 42, 1174-1182 10.1134/S1070428006080124
26. Malovichko, O. L.; Petrus, A. S.; Krysko, A. A.; Kabanova, T. A.; Andronati, S. A.; Karaseva, T. L.; Kiriyak, A. V. Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists Bioorg. Med. Chem. Lett. 2006, 16, 5294-5297 10.1016/j.bmcl.2006.07.090
27. Malovichko, O. L.; Krysko, A. A.; Kabanova, T. A.; Andronati, S. A.; Grishkovets, V. I.; Kachala, V. V.; Panov, D. A. Derivatives of 1,2,3,4-tetrahydroisoquinoline-7-carboxylic Acid as Novel Fibrinogen Receptor Antagonists Med. Chem. 2009, 5, 158-164 10.2174/157340609787582909
28. Krysko, A. A.; Krysko, O. L.; Kabanova, T. A.; Andronati, S. A.; Kabanov, V. M. Derivatives of tetrahydroisoquinoline: Synthesis and initial evaluation of novel non-peptide antagonists of the αIIbβ3-integrin Bioorg. Med. Chem. Lett. 2010, 20, 4444-4446 10.1016/j.bmcl.2010.06.051
29. Krysko, A. A.; Samoylenko, G. V.; Polishchuk, P. G.; Fonari, M. S.; Kravtsov, V. C.; Andronati, S. A.; Kabanova, T. A.; Lipkowski, J.; Khristova, T. M.; Kuzmin, V. E.; Kabanov, V. M.; Krysko, O. L.; Varnek, A. A. Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ3 Bioorg. Med. Chem. 2013, 21, 4646-4661 10.1016/j.bmc.2013.05.019
30. Breiman, L. Random forests Mach. Learning 2001, 45, 5-32 10.1023/A:1010933404324
31. Kuzmin, V. E.; Artemenko, A. G.; Polischuk, P. G.; Muratov, E. N.; Khromov, A. I.; Liahovskiy, A. V.; Andronati, S. A.; Makan, S. Y. Hierarchic System of QSAR Models (1D-4D) on the Base of Simplex Representation of Molecular Structure J. Mol. Model. 2005, 11, 457-467 10.1007/s00894-005-0237-x
32. Kuzmin, V. E.; Artemenko, A. G.; Muratov, E. N. Hierarchical QSAR technology based on the Simplex representation of molecular structure J. Comput.-Aided Mol. Des. 2008, 22, 403-421 10.1007/s10822-008-9179-6
33. Laboratoire de Chemoinformatique UMR 7140 CNRS, Université de Strasbourg, 1, rue B. Pascal, Strasbourg 67000, France. http://infochim.u-strasbg.fr/.
34. Bonachera, F.; Horvath, D. Fuzzy Tricentric Pharmacophore Fingerprints. 2. Application of Topological Fuzzy Pharmacophore Triplets in Quantitative Structure-Activity Relationships J. Chem. Inf. Model. 2008, 48, 409-425 10.1021/ci7003237
35. Bonachéra, F.; Parent, B.; Barbosa, F.; Froloff, N.; Horvath, D. Fuzzy Tricentric Pharmacophore Fingerprints. 1. Topological Fuzzy Pharmacophore Triplets and Adapted Molecular Similarity Scoring Schemes J. Chem. Inf. Model. 2006, 46, 2457-2477 10.1021/ci6002416
36. Mehrotra, M. M.; Heath, J. A.; Smyth, M. S.; Pandey, A.; Rose, J. W.; Seroogy, J. M.; Volkots, D. L.; Nannizzi-Alaimo, L.; Park, G. L.; Lambing, J. L.; Hollenbach, S. J.; Scarborough, R. M. Discovery of Novel 2,8-Diazaspiro[4.5]decanes as Orally Active Glycoprotein IIb-IIIa Antagonists† J. Med. Chem. 2004, 47, 2037-2061 10.1021/jm030354b
37. Wagner, C. L.; Mascelli, M. A.; Neblock, D. S.; Weisman, H. F.; Coller, B. S.; Jordan, R. E. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets Blood 1996, 88, 907-914
38. Xia, Z.; Wong, T.; Liu, Q.; Kasirer-Friede, A.; Brown, E.; Frojmovic, M. M. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation Br. J. Haematol. 1996, 93, 204-214 10.1046/j.1365-2141.1996.445980.x
39. Holmes, M. B.; Sobel, B. E.; Schneider, D. J. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects Am. J. Cardiol. 1999, 84, 203-207 10.1016/S0002-9149(99)00235-0
40. Wolber, G.; Langer, T. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters J. Chem. Inf. Model. 2005, 45, 160-169 10.1021/ci049885e
41. Springer, T. A.; Zhu, J.; Xiao, T. Structural basis for distinctive recognition of fibrinogen γC peptide by the platelet integrin αIIbβ3 J. Cell Biol. 2008, 182, 791-800 10.1083/jcb.200801146
42. Cheng, S.; Craig, W. S.; Mullen, D.; Tschopp, J. F.; Dixon, D.; Pierschbacher, M. D. Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin.alpha.IIb.beta.3 antagonists J. Med. Chem. 1994, 37, 1-8 10.1021/jm00027a001
43. Ojima, I.; Dong, Q.; Chakravarty, S.; Peerschke, E.; Hwang, S. M.; Wong, A. S. Design, synthesis and SAR of RGD peptide hybrids as highly efficient inhibitors of platelet aggregation Bioorg. Med. Chem. Lett. 1995, 5, 1941-1946 10.1016/0960-894X(95)00329-R
44. FlexX, 2.1.2; BioSolveIT GmbH: Sankt Augustin, Germany.
45. Molecular Operating Environment (MOE), 2008.10; Chemical Computing Group Inc.: Montreal, QC, Canada.
46. Korb, O.; Stützle, T.; Exner, T. In PLANTS: Application of Ant Colony Optimization to Structure-Based Drug Design. Ant Colony Optimization and Swarm Intelligence; Dorigo, M.; Gambardella, L.; Birattari, M.; Martinoli, A.; Poli, R.; Stützle, T., Eds.; Springer: Berlin/Heidelberg, 2006; Vol. 4150, pp 247-258.
47. Korb, O.; Stützle, T.; Exner, T. E. Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS J. Chem. Inf. Model. 2009, 49, 84-96 10.1021/ci800298z
48. Korb, O.; Stützle, T.; Exner, T. An ant colony optimization approach to flexible protein-ligand docking Swarm Intelligence 2007, 1, 115-134 10.1007/s11721-007-0006-9
49. Rognan, D. BioinfoDB: un inventaire de molécules commercialement disponibles à des fins de criblage biologique La Gazette du CINES 2005, 1-4
50. ISIDA Predictor. http://infochim.u-strasbg.fr/cgi-bin/predictor.cgi?GeneralPropSelect=PhysProp.
51. Muratov, E. N.; Kuzmin, V. E.; Artemenko, A. G.; Kovdienko, N. A.; Gorb, L.; Hill, F.; Leszczynski, J. New QSPR equations for prediction of aqueous solubility for military compounds Chemosphere 2010, 79, 887-890 10.1016/j.chemosphere.2010.02.030
52. Sushko, I.; Novotarskyi, S.; Korner, R.; Pandey, A. K.; Cherkasov, A.; Li, J.; Gramatica, P.; Hansen, K.; Schroeter, T.; Muller, K.; Xi, L.; Liu, H.; Yao, X.; Oberg, T.; Hormozdiari, F.; Dao, P.; Sahinalp, C.; Todeschini, R.; Polishchuk, P.; Artemenko, A.; Kuzmin, V.; Martin, T. M.; Young, D. M.; Fourches, D.; Muratov, E.; Tropsha, A.; Baskin, I.; Horvath, D.; Marcou, G.; Muller, C.; Varnek, A.; Prokopenko, V. V.; Tetko, I. V. Applicability Domains for Classification Problems: Benchmarking of Distance to Models for Ames Mutagenicity Set J. Chem. Inf. Model. 2010, 50, 2094-2111 10.1021/ci100253r
53. Poroikov, V.; Filimonov, D.; Lagunin, A.; Gloriozova, T.; Zakharov, A. PASS: identification of probable targets and mechanisms of toxicity SAR QSAR Environ. Res. 2007, 18, 101-10 10.1080/10629360601054032
54. Advanced and HTS Enamine Databases. http://www.enamine.net/index.php?option=com
55. REAL Enamine Database. http://www.enamine.net/index.php?option=com
56. Irwin, J. J.; Shoichet, B. K. ZINC-A Free Database of Commercially Available Compounds for Virtual Screening J. Chem. Inf. Model. 2005, 45, 177-182 10.1021/ci049714+
57. Aoyama, T.; Ino, Y.; Ozeki, M.; Oda, M.; Sato, T.; Koshiyama, Y.; Suzuki, S.; Fujita, M. Pharmacological Studies of Fut-175, Nafamostat Mesilate 0.1. Inhibition of Protease Activity in Invitro and Invivo Experiments Jpn. J. Pharmacol. 1984, 35, 203-227 10.1254/jjp.35.203
58. Negri, A.; Li, J.; Naini, S.; Coller, B. S.; Filizola, M. Structure-based virtual screening of small-molecule antagonists of platelet integrin alphaIIbbeta3 that do not prime the receptor to bind ligand J. Comput.-Aided Mol. Des. 2012, 26, 1005-15 10.1007/s10822-012-9594-6
59. Pâques, E. P.; Römisch, J. Comparative study on the in vitro effectiveness of antithrombotic agents Thromb. Res. 1991, 64, 11-21 10.1016/0049-3848(91)90201-7
60. Tsuda, Y.; Nakahara, T.; Ueda, K.; Mori, A.; Sakamoto, K.; Ishii, K. Effect of Nafamostat on N-Methyl-D-aspartate-Induced Retinal Neuronal and Capillary Degeneration in Rats Biol. Pharm. Bull. 2012, 35, 2209-2213 10.1248/bpb.b12-00644
61. Inman, R.; Chiu, B. Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis Arthritis Res. Ther. 2012, 14, R150 10.1186/ar3886
62. Ohtake, Y.; Hirasawa, H.; Sugai, T.; Oda, S.; Shiga, H.; Matsuda, K.; Kitamura, N. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration Contrib. Nephrol. 1991, 93, 215-7 10.1159/000420222
63. Nakae, H.; Tajimi, K. Pharmacokinetics of nafamostat mesilate during continuous hemodiafiltration with a polyacrylonitrile membrane Ther. Apheresis Dial. 2003, 7, 483-5 10.1046/j.1526-0968.2003.00088.x
64. Liverton, N. J.; Armstrong, D. J.; Claremon, D. A.; Remy, D. C.; Baldvin, J. J.; Lynch, R. J.; Zhang, G.; Gould, R. J. Nonpeptide glycoprotein IIb/IIIa inhibitors: Substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists Bioorg. Med. Chem. Lett. 1998, 8, 483-486 10.1016/S0960-894X(98)00047-X
65. Westwood, R.; Tully, W. R.; Murdoch, R. Antihistaminic and bronchospasmolytic triazoloquinazolinones. US4350695 A, 21 September, 1982.
66. Wang, Y.; Zhao, Y.; Sun, R.; Kong, W.; Wang, B.; Yang, G.; Li, Y. Discovery of novel antagonists of glycoprotein IIb/IIIa-mediated platelet aggregation through virtual screening Bioorg. Med. Chem. Lett. 2015, 25, 1249-1253 10.1016/j.bmcl.2015.01.053
67. Born, G. V. R. Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 1962, 194, 3 10.1038/194927b0
68. Standartizer, 5.4; Chemaxon: Budapest, Hungary.
69. Instant JChem, 5.4; Chemaxon: Budapest, Hungary.
70. Muratov, E. N.; Artemenko, A. G.; Varlamova, E. V.; Polischuk, P. G.; Lozitsky, V. P.; Fedchuk, A. S.; Lozitska, R. L.; Gridina, T. L.; Koroleva, L. S.; Silnikov, V. N.; Galabov, A. S.; Makarov, V. A.; Riabova, O. B.; Wutzler, P.; Schmidtke, M.; Kuzmin, V. E. Per aspera ad astra: application of Simplex QSAR approach in antiviral research Future Med. Chem. 2010, 2, 1205-1226 10.4155/fmc.10.194
71. Polishchuk, P. G. Random Forest software (CF), version 2.13; 2010.
72. Svetnik, V.; Liaw, A.; Tong, C.; Culberson, J. C.; Sheridan, R. P.; Feuston, B. P. Random forest: A classification and regression tool for compound classification and QSAR modeling J. Chem. Inf. Model. 2003, 43, 1947-1958 10.1021/ci034160g
73. Polishchuk, P. G.; Muratov, E. N.; Artemenko, A. G.; Kolumbin, O. G.; Muratov, N. N.; Kuzmin, V. E. Application of Random Forest Approach to QSAR Prediction of Aquatic Toxicity J. Chem. Inf. Model. 2009, 49, 2481-2488 10.1021/ci900203n
74. Kovdienko, N. A.; Polishchuk, P. G.; Muratov, E. N.; Artemenko, A. G.; Kuzmin, V. E.; Gorb, L.; Hill, F.; Leszczynski, J. Application of Random Forest and Multiple Linear Regression Techniques to QSPR Prediction of an Aqueous Solubility for Military Compounds Mol. Inf. 2010, 29, 394-406 10.1002/minf.201000001
75. Ognichenko, L. N.; Kuzmin, V. E.; Gorb, L.; Hill, F. C.; Artemenko, A. G.; Polischuk, P. G.; Leszczynski, J. QSPR Prediction of Lipophilicity for Organic Compounds Using Random Forest Technique on the Basis of Simplex Representation of Molecular Structure Mol. Inf. 2012, 31, 273-280 10.1002/minf.201100102
76. Hansen, K.; Mika, S.; Schroeter, T.; Sutter, A.; ter Laak, A.; Steger-Hartmann, T.; Heinrich, N.; Müller, K.-R. Benchmark Data Set for in Silico Prediction of Ames Mutagenicity J. Chem. Inf. Model. 2009, 49, 2077-2081 10.1021/ci900161g
77. Filter, 2.0.2; OpenEye Scientific Software, Inc.: Santa Fe, NM, 2010.
78. Omega, 2.4.3; OpenEye Scientific Software, Inc.: Santa Fe, NM, 2010.
79. OEChem, 1.7.4; OpenEye Scientific Software, Inc.: Santa Fe, NM, 2010.
80. cxcalc, 5.4; Chemaxon: Budapest, Hungary.
81. a based protonation states and microspecies for protein-ligand docking J. Comput.-Aided Mol. Des. 2010, 24, 935-942 10.1007/s10822-010-9385-x
82. Schrodinger, L. L. C. The PyMOL Molecular Graphics System, version 1.3r1; 2010.
83. Askew, B. C.; Bednar, R. A.; Bednar, B.; Claremon, D. A.; Cook, J. J.; McIntyre, C. J.; Hunt, C. A.; Gould, R. J.; Lynch, R. J.; Lynch, J. J.; Gaul, S. L.; Stranieri, M. T.; Sitko, G. R.; Holahan, M. A.; Glass, J. D.; Hamill, T.; Gorham, L. M.; Prueksaritanont, T.; Baldwin, J. J.; Hartman, G. D. Non-Peptide Glycoprotein IIb/IIIa Inhibitors. 17. Design and Synthesis of Orally Active, Long-Acting Non-Peptide Fibrinogen Receptor Antagonists J. Med. Chem. 1997, 40, 1779-1788 10.1021/jm9608117
84. Duggan, M. E.; Duong, L. T.; Fisher, J. E.; Hamill, T. G.; Hoffman, W. F.; Huff, J. R.; Ihle, N. C.; Leu, C.-T.; Nagy, R. M.; Perkins, J. J.; Rodan, S. B.; Wesolowski, G.; Whitman, D. B.; Zartman, A. E.; Rodan, G. A.; Hartman, G. D. Nonpeptide αvβ3 Antagonists. 1. Transformation of a Potent, Integrin-Selective αIIbβ3 Antagonist into a Potent αvβ3 Antagonist J. Med. Chem. 2000, 43, 3736-3745 10.1021/jm000133v
85. Hantgan, R. R. An investigation of fibrin-platelet adhesive interactions by microfluorimetry Biochim. Biophys. Acta, Mol. Cell Res. 1987, 927, 55-64 10.1016/0167-4889(87)90065-6